Vaxart Inc. (NASDAQ:VXRT) has a beta value of 0.22 and has seen 106,000,000 shares traded in the last trading session. The company, currently valued at $1.27 Billion, closed the last trade at $10.78 per share which meant it gained $1.57 on the day or 17.05% during that session. The VXRT stock price is -130.98% off its 52-week high price of $24.9 and 84.97% above the 52-week low of $1.62. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.94 Million shares traded. The 3-month trading volume is 14.58 Million shares.
The consensus among analysts is that Vaxart Inc. (VXRT) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.1.
Vaxart Inc. (NASDAQ:VXRT) trade information
Sporting 17.05% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, Apr 30 when the VXRT stock price touched $11.11- or saw a rise of 2.95%. Year-to-date, Vaxart Inc. shares have moved 88.79%, while the 5-day performance has seen it change 93.88%. Over the past 30 days, the shares of Vaxart Inc. (NASDAQ:VXRT) have changed 86.18%. Short interest in the company has seen 25.61 Million shares shorted with days to cover at 1.76.
Wall Street analysts have a consensus price target for the stock at $11.5, which means that the shares’ value could jump 6.68% from current levels. The projected low price target is $10 while the price target rests at a high of $13. In that case, then, we find that the current price level is +20.59% off the targeted high while a plunge would see the stock lose -7.24% from current levels.
Vaxart Inc. (VXRT) estimates and forecasts
Figures show that Vaxart Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +115.6% over the past 6 months, with this year growth rate of -86.11%, compared to 16.6% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -400% and 8.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be +551.3%.
2 analysts offering their estimates for the company have set an average revenue estimate of $620Million for the current quarter. 2 have an estimated revenue figure of $750Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $2.8 Million for this quarter, and analysts expect sales will grow by -77.9% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +45% over the past 5 years. Earnings growth for 2021 is a modest +57.8%.
Vaxart Inc. (NASDAQ:VXRT)’s Major holders
Insiders own 0.6% of the company shares, while shares held by institutions stand at 34.33% with a share float percentage of 34.54%. Investors are also buoyed by the number of investors in a company, with Vaxart Inc. having a total of 200 institutions that hold shares in the company. The top two institutional holders are State Street Corporation with over 9.44 Million shares worth more than $53.93 Million. As of December 30, 2020, State Street Corporation held 8.02% of shares outstanding.
The other major institutional holder is Vanguard Group Inc. (The), with the holding of over 5.16 Million shares as of December 30, 2020. The firm’s total holdings are worth over $29.48 Million and represent 4.38% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of March 30, 2021, the former fund manager holds about 6.19% shares in the company for having 7292366 shares of worth $44.12 Million while later fund manager owns 2.95 Million shares of worth $16.87 Million as of December 30, 2020, which makes it owner of about 2.51% of company’s outstanding stock.